Open Access
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +15 more
Reads0
Chats0
TLDR
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.About:
The article was published on 2017-04-01 and is currently open access. It has received 169 citations till now. The article focuses on the topics: Alzheimer's Disease Neuroimaging Initiative & Biomarker (medicine).read more
Citations
More filters
Journal ArticleDOI
Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks
Silvia Basaia,Federica Agosta,Luca Wagner,Elisa Canu,Giuseppe Magnani,Roberto Santangelo,Massimo Filippi +6 more
TL;DR: A deep learning algorithm is built and validated predicting the individual diagnosis of Alzheimer's disease and mild cognitive impairment who will convert to AD (c-MCI) based on a single cross-sectional brain structural MRI scan, demonstrating that it is exploitable by not-trained operators and likely to be generalizable to unseen patient data.
Journal ArticleDOI
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +14 more
TL;DR: Select topics that provide insights into AD progression are discussed and how this knowledge may improve clinical trials are outlined.
Journal ArticleDOI
Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
TL;DR: This paper proposes a novel deep-learning-based framework to discriminate individuals with AD utilizing a multimodal and multiscale deep neural network and delivers 82.4% accuracy and 94.23% sensitivity in classifying individuals with clinical diagnosis of probable AD.
Journal ArticleDOI
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.
Kwangsik Nho,Alexandra Kueider-Paisley,Siamak MahmoudianDehkordi,Matthias Arnold,Shannon L. Risacher,Gregory Louie,Colette Blach,Rebecca Baillie,Xianlin Han,Gabi Kastenmüller,Wei Jia,Guoxiang Xie,Shahzad Ahmad,Thomas Hankemeier,Cornelia M. van Duijn,John Q. Trojanowski,Leslie M. Shaw,Michael W. Weiner,P. Murali Doraiswamy,Andrew J. Saykin,Rima Kaddurah-Daouk +20 more
TL;DR: In this paper, the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF), atrophy (magnetic resonance imaging), and brain glucose metabolism (FDG PET).
Journal ArticleDOI
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
Marc Suárez-Calvet,Marc Suárez-Calvet,Estrella Morenas-Rodríguez,Estrella Morenas-Rodríguez,Gernot Kleinberger,Kai Schlepckow,Miguel Ángel Araque Caballero,Nicolai Franzmeier,Anja Capell,Katrin Fellerer,Brigitte Nuscher,Erden Eren,Erden Eren,Johannes Levin,Johannes Levin,Yuetiva Deming,Laura Piccio,Celeste M. Karch,Carlos Cruchaga,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Michael Ewers,Christian Haass,Christian Haass +24 more
TL;DR: CSF sTREM2 increased in early symptomatic stages of late-onset AD but, unexpectedly, was observed decreased at the earliest asymptomatic phase when only abnormal Aβ pathology but no tau pathology or neurodegeneration, is present.
References
More filters
Journal ArticleDOI
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Susan M. Landau,Susan M. Landau,Benjamin A. Thomas,Lennart Thurfjell,Mark E. Schmidt,Richard Margolin,Mark A. Mintun,Michael J. Pontecorvo,Suzanne L. Baker,William J. Jagust,William J. Jagust +10 more
TL;DR: Despite differing white and grey matter retention characteristics, cortical retention for each 18F tracer was highly correlated with that of PiB, enabling conversion of thresholds across tracer measurement scales with a high level of internal consistency.
Journal Article
Cascading Network Failure across the Alzheimer’s Disease Spectrum (I12.010)
David T.W. Jones,David S. Knopman,Jeffery Gunter,Jonathan Graff-Radford,Prashanthi Vemuri,Bradley F. Boeve,Ronald C. Petersen,Michael W. Weiner,Clifford R. Jack +8 more
TL;DR: In this paper, the authors investigated AD-related changes in distributed brain networks and found that high connectivity between the pDMN and other subsystems is associated with amyloidosis.
Journal ArticleDOI
Down syndrome and Alzheimer's disease: Common pathways, common goals.
Dean M. Hartley,Thomas Blumenthal,Maria C. Carrillo,Gilbert DiPaolo,Lucille Esralew,Katheleen Gardiner,Katheleen Gardiner,Ann-Charlotte Granholm,Khalid Iqbal,Michael Krams,Cynthia A. Lemere,Ira T. Lott,William C. Mobley,Seth Ness,Ralph A. Nixon,Huntington Potter,Huntington Potter,Roger H. Reeves,Marwan N. Sabbagh,Wayne Silverman,Wayne Silverman,Benjamin Tycko,Michelle Sie Whitten,Thomas Wisniewski +23 more
TL;DR: A workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field articulated a set of research priorities: target identification and drug development, clinical and pathological staging, cognitive assessment and clinical trials, and partnerships and collaborations with the ultimate goal to deliver effective disease‐modifying treatments.
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Jesse M. Cedarbaum,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Johan Luthman,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Li Shen,Adam J. Schwarz,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +19 more
Journal ArticleDOI
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE
TL;DR: It is shown that baseline CSF ferritin levels were negatively associated with cognitive performance over 7 years in 91 cognitively normal, 144 mild cognitive impairment and 67 AD subjects, and predicted MCI conversion to AD.
Related Papers (5)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Jesse M. Cedarbaum,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Johan Luthman,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Li Shen,Adam J. Schwarz,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +19 more
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Charles DeCarli,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Susan M. Landau,John C. Morris,Ozioma C. Okonkwo,Richard J. Perrin,Ronald C. Petersen,Monica Rivera-Mindt,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,Duygu Tosun,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +20 more